<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4555">
  <stage>Registered</stage>
  <submitdate>6/01/2014</submitdate>
  <approvaldate>6/01/2014</approvaldate>
  <nctid>NCT02029885</nctid>
  <trial_identification>
    <studytitle>Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension</studytitle>
    <scientifictitle>Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension</scientifictitle>
    <utrn />
    <trialacronym>WAVE_IV</trialacronym>
    <secondaryid>KM14-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Investigational Therapy (Surround Sound)
Treatment: devices - Sham Control

Experimental: Investigational Therapy (Surround Sound) - Investigational Therapy using external focused ultrasound

Sham Comparator: Sham Control - Blinded Sham Control Arm


Treatment: devices: Investigational Therapy (Surround Sound)


Treatment: devices: Sham Control


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety at 6 weeks follow-up - Safety will be assessed by incidence of Major Adverse Events (MAE), defined as a composite of the following events at 6-weeks follow-up.
All cause mortality;
End-stage Renal Disease defined as eGFR &lt; 15 ml/min or need for renal replacement therapy
Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications as assessed by toxicological and other medical analyses and testing.
OR
- New renal artery stenosis &gt; 70% confirmed by angiography within 6 months of randomization</outcome>
      <timepoint>6 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in OBP - Change in Office Systolic Blood Pressure (OBP) as measured from screening visit one to the 6 month post randomization follow-up visit.</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in ABPM - Change in average 24-hour ambulatory blood pressure from screening to the 6 month follow-up visit</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subject is at least 18 years of age and no more than 90 years of age

          2. Average SBP = 160 mmHg

          3. 24 hour average ABPM daytime SBP = 135 mmHg.

          4. No medication changes for a minimum of 1 months prior to screening.

          5. At minimum, subject must be on at least three antihypertensive medications, with one
             being a diuretic, and each must meet one or more of the following full dose criteria:

               1. Highest labeled dose according to medication's labeling;

               2. Highest usual dose per clinical guidelines JNC-7;

               3. Highest tolerated dose; and/or

               4. Highest appropriate dose for the subject per the PI's clinical judgment.

          6. Subject has two functioning kidneys.

          7. Subject has an eGFR value of = 30 ml/min/1.73 m² (MDRD formula).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subject has any secondary cause of hypertension

          2. Subject has evidence of clinically significant renal artery stenosis as determined by
             flow rate, velocity and Doppler analysis on ultrasound

          3. Subject has kidney stones that are of a size and location that are determined at
             discretion of the investigator to potentially interfere with treatment

          4. Subject has a history of intra-abdominal surgery within the past six months

          5. Subject has heterogeneities in the kidney such as large cysts or tumors that are
             determined at discretion of the investigator to potentially interfere with treatment.

          6. Stenotic valvular heart disease for which BP reduction would be hazardous as
             determined by referring physician.

          7. MI, unstable angina, or CVA in the prior 6 months.

          8. Known severe primary pulmonary HTN

          9. Subject has a history of myocardial infarction, unstable angina pectoris, or
             cerebrovascular accident within the last six months.

         10. Subject has hemodynamically significant valvular heart disease.

         11. Subject has BMI over 40 km/m^2

         12. Subject has a target treatment depth over 13 cm.

         13. Subject has anatomy that precludes treatment with the Kona Medical Surround Sound
             System.

         14. Subject is pregnant, nursing, or intends to become pregnant during the trial period.

         15. Subject is currently enrolled in other potentially confounding research.

         16. Subject has any condition that, at the discretion of the investigator, would preclude
             participation in the trial.

         17. Subject is unable, or unwilling, to comply with the protocol-required follow-up
             schedule</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>132</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Monash Medical Centre - Clayton</hospital>
    <postcode> - Clayton</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cali</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Luebeck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Münster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Aukland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Exeter</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Kona Medical Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To demonstrate that non-invasive renal denervation is safe and shows a net difference in
      blood pressure reduction when compared to sham in subjects with uncontrolled hypertension.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02029885</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Roland Schmieder, MD</name>
      <address>University Hospital of University of Erlangen-Nuremberg</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Omar Dawood</name>
      <address />
      <phone />
      <fax />
      <email>odawood@konamedical.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>